Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 113
- 试验地点
- 29
- 主要终点
- Progression free survival
研究概览
简要总结
HALT is a phase II, randomised multi-centre study with integrated seamless continuation to phase III trial following acceptable safety and feasibility assessment.
HALT aims to recruit 110 patients with mutation positive advanced NSCLC with oligoprogressive disease (OPD) following initial response to a Tyrosine Kinase Inhibitor (TKI).
详细描述
Eligible patients will be randomised to receive either SBRT or no SBRT at a ratio of 2:1 (SBRT : no SBRT), with all patients continuing to receive background treatment with TKI therapy as clinically indicated and as per standard care. Patients randomised to receive SBRT will receive a dose and fractionation schedule dependent on OPD lesion site and proximity to critical normal tissues. All patients will be seen 8 weeks post randomisation, then 3 monthly in line with routine care.
HALT aims to assess whether in patients with mutation positive advanced NSCLC the use of SBRT to ≤ 3 sites of OPD with continuation of TKI improves progression-free survival (PFS) compared with continuation of TKI alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, ≥ 16 years of age
- •Established histological diagnosis of advanced NSCLC, not suitable for radical treatment, with defined actionable mutation receiving targeted TKI therapy
- •Clinical and/or radiologically confirmed response to TKI therapy (assessed locally usually 2-3 months post commencing TKI)
- •Confirmed OPD defined as ≤ 5 extracranial sites of progressive disease. All sites must be visible, imaging defined targets and suitable for treatment with SBRT as determined by the virtual multi-disciplinary team (MDT) and in accordance with the HALT Radiotherapy planning and delivery guidance document.
- •Adequate baseline organ function to allow SBRT to all relevant targets
- •Predicted life expectancy ≥ 6 months
- •Karnofsky Index ≥ 60% and ECOG 0-2
- •Provision of written informed consent
排除标准
- •> 5 extracranial sites of progressive disease
- •Progressing or newly diagnosed brain metastases identified at the time of trial entry, not amenable to radical surgery or SRS. Previously treated brain metastases (i.e palliative radiotherapy or systemic therapy) which have remained clinically and radiologically stable for ≥ 6 months are permissible.
- •Prior radiotherapy near the oligoprogressive lesion precluding ablative SBRT. Suitability of lesions for ablative SBRT as part of the trial defined in section 4.1 of this document and will be determined by the HALT virtual MDT
- •Co-morbidities considered clinically precluding the safe use of SBRT (as detailed in the HALT radiotherapy planning and delivery guidelines).
- •Any psychological, sociological or geographical issue potentially hampering compliance with the study
研究组 & 干预措施
SBRT and continued TKI therapy
Patients will continue to receive background TKI treatment as prior to trial entry.
Simultaneous administration (SBRT & TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.
Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 5.
干预措施: SBRT (Radiation)
Continued TKI therapy alone
Continuation on the same background TKI treatment as prior to trial entry
干预措施: TKI (Drug)
结局指标
主要结局
Progression free survival
时间窗: Time from randomisation to the first of one of the above events or death. Assessed 8 weeks post-randomisation and 3-monthly thereafter (up to 24 months)
The primary outcome measure is progression free survival defined as the time from randomisation to the first of one of the following events or death from any cause: * Clinically symptomatic progression requiring palliative tumour-specific oncological intervention (e.g. change in systemic therapy or localised non-SBRT radiotherapy) as determined by the treating physician. * New or existing intra-cranial lesions not amenable to radical surgery or Stereotactic radiosurgery (SRS). * Development of new extra-cranial lesions or progression of existing extra-cranial lesions not meeting the criteria for * SBRT treatment (e.g. size \>7cm) * Development of \>5 new or progressing extra-cranial lesion at any one point in time (i.e. widespread progression)
次要结局
- Measurement of resistant sub-clones in Circulating tumour DNA (ctDNA)(Baseline, 8 weeks post-randomisation and 3-monthly intervals during follow-up (up to 24 months).)
- Overall survival(Time from randomisation until death from any cause. Assessed up to 24 months.)
- Radiotherapy toxicities (acute events)(Baseline, 8 weeks and 3-monthly intervals during follow-up (a minimum of 6 months).)
- Patterns of disease progression identified from CT scans to further document natural history of oncogene-addicted NSCLC(Assessed 3-monthly up to 24 months.)
- Quality of Life (EQ-5D-5L)(Baseline, 8 weeks and at the first 3 month visit.)
- Time to failure of next line treatment(Time from randomisation to disease progression on next line of active systemic therapy. Assessed up to 24 months.)
- Time to next line of systemic therapy or palliative care(Time from randomisation to change in therapy or referral to palliative care due to clinical progression as determined by the treating physician, or death. Assessed 3-monthly until progression and 6-monthly thereafter (up to 24 months).)
- Radiotherapy toxicities (late events)(Baseline, 8 weeks and 3-monthly intervals during follow-up (a minimum of 6 months).)
- Quality of Life (EORTC QLQ-C30)(Baseline, 8 weeks and at the first 3 month visit.)